Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for PetVivo Holdings, Inc. (PETVW warrants, PETV common stock) provides direct access to the company’s official regulatory disclosures. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information about corporate events, governance changes, investor communications and financial presentations that are relevant to understanding the business underlying the PETVW warrants.
Recent Form 8-K filings illustrate how PetVivo reports material events. For example, one Form 8-K describes the appointment of an independent director to the board and the expansion of the board’s size, while another notes the resignation of a director and a corresponding reduction in the number of board seats. Other 8-K filings furnish investor presentations under Regulation FD, making slide decks and related materials part of the public record without treating them as filed for liability purposes.
Through its filings, PetVivo identifies itself as a Nevada corporation with a specific Commission File Number and employer identification number, and it provides its corporate telephone contact. These documents complement the company’s news releases that describe its focus on manufacturing, commercialization and licensing of veterinary medical devices and therapeutics for companion animals and horses, as well as its AI initiatives via PetVivo AI, Inc. and the PetVivo.ai platform.
On Stock Titan, this filings page is updated as new PetVivo documents are posted to the SEC’s EDGAR system, enabling users to review 8-Ks, investor presentations and other reports in one place. AI-powered tools can help summarize key points from lengthy filings, highlight sections related to board composition, strategic agreements or investor communications, and make it easier to connect these disclosures with the performance of the underlying PETVW warrants.
PetVivo Holdings, Inc. reported another loss-making quarter for the period ended December 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern. Quarterly revenue fell to $286,108 from $583,313 a year earlier, while the net loss available to common stockholders widened to $2,316,455. For the nine months, revenue was $886,892 versus $907,783, with a net loss of $7,788,904. Cash dropped to just $18,164, against an accumulated deficit of $98,987,394. The company shifted away from prior distributors, now relying heavily on Vedco for most sales, and added new licensing agreements for PrecisePRP and an AI platform that it expects to drive future revenue.
PetVivo Holdings, Inc. reported a change in its Board of Directors. On January 26, 2026, director Spencer Breithaupt resigned from the Board, effective that day. The company states his resignation was not due to any disagreement over operations, policies, or practices.
Following his departure, the Board reduced its size from seven to six directors and does not plan to immediately fill the vacancy, though it may add a seventh director in the future at its discretion. The Board expressed appreciation for Mr. Breithaupt’s leadership, guidance, and contributions during his service.
PetVivo Holdings, Inc. furnished a new investor presentation as part of a current report. Representatives plan to use this January 2026 presentation at investor conferences, in other forums, and on the company’s website.
The presentation is included as Exhibit 99.1 and is furnished under Regulation FD and Item 7.01, meaning it is not deemed filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced. Management notes that the information is summary in nature and may be updated over time through future SEC reports, press releases, or other public disclosures.
PetVivo Holdings, Inc. investor updates ownership report. Individual shareholder Stanley Cruden reports beneficial ownership of 3,620,163 shares of PetVivo common stock, representing 9.37% of the class, as of the event date of 12/31/2025. He has sole power to vote and dispose of all these shares and reports no shared voting or dispositive power.
The certification states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PetVivo Holdings, Inc., nor in connection with any control-related transaction, other than activities solely in connection with a nomination under the cited proxy rule.
PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.
PetVivo Holdings (PETV) reported Q2 FY2026 results. Revenue was $303,284 versus $200,720 a year ago, driven mainly by sales to Vedco after prior distributor agreements were terminated. Gross profit was $220,058. The company recorded a net loss of $3,007,809 for the quarter and $5,318,846 for the six months.
Cash was $767,914 and stockholders’ equity $4,182,972 at September 30, 2025. Total liabilities fell to $1,075,297 from $5,119,947, reflecting the conversion of $1,850,000 in convertible notes plus interest into 3,669,806 shares and the elimination of derivative liabilities. Operating cash outflow was $3,828,209 for the six months, partly offset by $4,361,829 of financing inflows, including receipt of the remaining $4,400,000 under the $5,000,000 Series B Preferred subscription (10% annual dividend payable in stock).
The company added two licensing assets: VetStem PRP ($2,000,000 fee) and an AI software license ($800,000 paid in stock). Shares outstanding were 33,580,630 as of November 14, 2025. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
A.L. Sarroff Fund, LLC filed Amendment No. 10 to Schedule 13G reporting beneficial ownership of 8,846,288 shares of PetVivo Holdings, Inc. common stock, representing 31.7% of the class. The filer reports sole voting and sole dispositive power over the same 8,846,288 shares, with no shared power.
The filing states reliance on Rule 13d-1(c) and certifies the securities were not acquired to change or influence control. It also discloses 4,780,008 warrants with specified future exercisability dates that are not included in the Schedule 13G ownership per Rule 13d-3(d)(1). As context, the issuer had 27,903,361 shares outstanding as of August 14, 2025, and the filer notes its holdings were 26.5% as of June 30, 2025.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.
PetVivo Holdings (PETV) reported an insider transaction on Form 4. Chief Financial Officer Garry Lowenthal received 75,000 shares of restricted common stock on 10/23/2025 at a reported price of $1.27 per share. The grant was issued to a corporation owned by him as compensation for past performance. After this grant, he beneficially owns 667,967 shares, held indirectly through the corporation.